SPX3,825.33+39.95 1.06%
DIA310.85+3.03 0.98%
IXIC11,127.85+99.11 0.90%

BRIEF-Oncternal Therapeutics Presents Plans For Registrational Phase 3 Study Evaluating Zilovertamab In Combination With Ibrutinib

reuters.com · 06/10/2022 09:12
BRIEF-Oncternal Therapeutics Presents Plans For Registrational Phase 3 Study Evaluating Zilovertamab In Combination With Ibrutinib

- Oncternal Therapeutics Inc ONCT:

  • ONCTERNAL THERAPEUTICS PRESENTS RATIONALE AND PLANS FOR ITS REGISTRATIONAL PHASE 3 STUDY EVALUATING ZILOVERTAMAB IN COMBINATION WITH IBRUTINIB AT THE EHA 2022 CONGRESS

Source text for Eikon: ID:nGNX5wtGdP

Further company coverage: ONCT


((reuters.briefs@thomsonreuters.com;))